'In the ideal position': Neuren Pharmaceuticals books profit and looks to second treatment after positive results

'In the ideal position': Neuren Pharmaceuticals books profit and looks to second treatment after positive results
Neuren Pharmaceuticals chief executive Jon Pilcher. (Image: Neuren Pharmaceuticals)
Rebecca Stevenson
Listed pharmaceutical firm Neuren says it is expecting to earn up to A$150 million in royalties in the US for its groundbreaking treatment for Rett Syndrome. Neuren, listed on the Australian Securities Exchange, posted its half-year result for the six months to June 30 on Tuesday. The New Zealand registered company posted an A$8m (NZ$8.7m) after-tax profit, which was a fall from the prior comparable half of $39.8m. Neuren said on Tuesday it earned royalty income of A$24.3m, an increase from A$3.5m in the first half of the 2023 fi...

More Markets

NZ sharemarket rises on back of positive news
Markets Market close

NZ sharemarket rises on back of positive news

The S&P/NZX 50 Index closed at 13,041.9, rising 276.66 points or 2.17%

Graham Skellern 22 Nov 2024
Oceania shrinks footprint, prioritises balance sheet
Property

Oceania shrinks footprint, prioritises balance sheet

Oceania has divested four aged care facilities in the space of six months.

Gregor Thompson 22 Nov 2024
The Warehouse’s plan to come back ‘with a vengeance’
Retail

The Warehouse’s plan to come back ‘with a vengeance’

Executives face tough questions at the retailer’s AGM.

Victoria Young 22 Nov 2024
Wellington's blue sky boondoggle
Infrastructure

Pattrick Smellie: Wellington's blue sky boondoggle

Is the capital's airport serious, or is Infratil just trying to pump value?

Pattrick Smellie 22 Nov 2024